Spyre Therapeutics Inc. (SYRE)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
21.54
0.74 (3.56%)
At close: Jan 15, 2025, 11:01 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
Revenue | 886.00K | 2.33M | 18.74M | n/a | n/a | 3.89M | 5.21M | 4.63M | 6.08M | n/a |
Cost of Revenue | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | n/a | n/a | n/a | 89.00K | 19.00K |
Gross Profit | -78.00K | 365.00K | 16.74M | -1.62M | -901.00K | 3.89M | 5.21M | 4.63M | 6.00M | -19.00K |
Operating Income | -242.30M | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.31M | -8.90M |
Interest Income | 6.15M | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1K |
Pretax Income | -338.82M | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.29M | -10.35M |
Net Income | -338.79M | -83.81M | -65.80M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.29M | -10.35M |
Selling & General & Admin | 39.95M | 28.53M | 27.32M | 21.84M | 14.83M | 12.34M | 9.82M | 8.26M | 5.95M | 2.06M |
Research & Development | 89.50M | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
Other Expenses | 113.74M | -7.00K | -122.00K | -5.00K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 79.43M | 49.06M | 32.63M | 26.40M | 17.40M | 8.88M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
Income Tax | -26.00K | -136.00K | 141.00K | -593.00K | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
Shares Outstanding (Diluted) | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
EPS (Basic) | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.4 | -25.2 | -18.91 |
EPS (Diluted) | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.4 | -25.2 | -18.91 |
EBITDA | -127.82M | -83.21M | -63.66M | -79.27M | -77.35M | -45.17M | -27.43M | -21.77M | -11.23M | -10.33M |
Depreciation & Amortization | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |